GlassScriptPhysician profile
Veena Gupta
NPI 1245332352
$7,808.70
in general payments reported to CMS, 2019-2025
24 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,008 · 2020: $329 · 2021: $888 · 2022: $915 · 2023: $881 · 2024: $1,384 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,667.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,663.46 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $1,119.67 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $893.13 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $703.23 | 2019-2022 | |
| Pfizer INC. | $461.40 | 2019-2025 | |
| Boston Scientific Corporation | $322.76 | 2019 | |
| Bridgebio Pharma, INC. | $322.44 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.28 | 2019-2023 | Jardiance |
| Abbott Laboratories | $276.66 | 2023-2024 | Mitraclip, Jot Dx |
| Otsuka America Pharmaceutical, INC. | $266.21 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $225.25 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $208.82 | 2019-2024 | Farxiga |
| Gilead Sciences, INC. | $166.45 | 2019 | |
| Amarin Pharma, INC. | $161.92 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Uzedy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Avanir Pharmaceuticals, INC. | $115.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $107.34 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $99.39 | 2023 | Inpefa |
| Neuronetics, INC. | $59.52 | 2019 | |
| Medicomp INC | $40.27 | 2025 | Telepatch Cardiac Monitor |
| Bardy Diagnostics, INC. | $19.13 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.